JTO Clinical and Research Reports

Scope & Guideline

Empowering Global Collaboration in Cancer and Respiratory Research

Introduction

Immerse yourself in the scholarly insights of JTO Clinical and Research Reports with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherELSEVIER
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJTO CLIN RES REP / JTO Clin. Res. Rep.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

JTO Clinical and Research Reports focuses on advancing knowledge and clinical practices in the field of lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The journal aims to disseminate high-quality research that informs clinical decision-making and improves patient outcomes.
  1. Clinical Research and Trials:
    The journal publishes findings from clinical trials, observational studies, and real-world evidence that contribute to the understanding of lung cancer treatments and their efficacy.
  2. Molecular and Genetic Insights:
    Research focusing on the molecular and genetic characteristics of lung cancer, including mutations, fusions, and biomarkers that influence treatment responses.
  3. Innovative Therapies and Treatment Approaches:
    Emphasis on novel therapeutic strategies, including targeted therapies, immunotherapy, and combination treatments, to enhance the management of lung cancer.
  4. Patient-Centric Studies:
    Investigations into patient-reported outcomes, quality of life, and treatment experiences to ensure that clinical practices align with patient needs.
  5. Epidemiology and Health Disparities:
    Exploration of the epidemiological trends in lung cancer, as well as socio-economic and racial disparities that impact access to care and treatment outcomes.
Recent publications in JTO Clinical and Research Reports highlight several emerging themes and trends that reflect the evolving landscape of lung cancer research and treatment. These trends indicate a shift towards more personalized and comprehensive approaches to care.
  1. Immunotherapy and Combination Treatments:
    There is a marked increase in studies examining the efficacy and safety of immunotherapy, particularly in combination with chemotherapy or targeted therapies, showcasing a trend towards multimodal treatment approaches.
  2. Real-World Evidence and Outcomes:
    A growing emphasis on real-world data studies that assess treatment effectiveness and safety in broader patient populations, reflecting the need for evidence that informs clinical practice in diverse settings.
  3. Molecular Profiling and Biomarker Research:
    An increasing focus on genomic profiling and biomarker studies to identify actionable targets and predict treatment responses, indicating a move towards precision medicine in lung cancer care.
  4. Patient-Centric Research:
    Emerging themes include studies that prioritize patient-reported outcomes and quality of life assessments, recognizing the importance of aligning treatment strategies with patient preferences and experiences.
  5. Health Disparities and Access to Care:
    An uptick in research addressing disparities in lung cancer treatment and outcomes based on socioeconomic status, race, and geographic location, pointing towards a more equitable approach in lung cancer care.

Declining or Waning

While the journal consistently covers a range of topics related to lung cancer, some areas have shown a decline in publication frequency and focus. The following themes appear to be waning.
  1. Traditional Chemotherapy Studies:
    Research focused solely on traditional chemotherapy regimens without integration of newer agents or immunotherapy has decreased, reflecting a shift towards more innovative treatment paradigms.
  2. Basic Science and Laboratory Studies:
    While foundational research is important, there has been a reduction in publications centered on basic laboratory studies without direct clinical implications, as the journal increasingly prioritizes clinical relevance.
  3. Single-Agent Studies:
    The focus on studies evaluating single-agent therapies has diminished, as combination therapies and multi-modal approaches are gaining prominence in treatment strategies.

Similar Journals

Current Problems in Cancer: Case Reports

Transforming patient care through diverse oncology perspectives.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

LUNG

Connecting researchers and clinicians in the fight against lung diseases.
Publisher: SPRINGERISSN: 0341-2040Frequency: 6 issues/year

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.

Pulmonology

Elevating knowledge and practice in pulmonary medicine.
Publisher: ELSEVIERISSN: 2531-0437Frequency: 6 issues/year

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Thoracic Cancer

Elevating the standards of oncology studies.
Publisher: WILEYISSN: 1759-7706Frequency: 24 issues/year

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

Turkish Thoracic Journal

Transforming the landscape of pulmonary medicine, one study at a time.
Publisher: AVESISSN: Frequency: 6 issues/year

Turkish Thoracic Journal, published by AVES, is a prominent open-access platform dedicated to advancing the field of pulmonary and respiratory medicine. Since its establishment, the journal has aimed to disseminate significant research findings, clinical studies, and reviews that contribute to an improved understanding of respiratory health challenges, with a particular focus on the Turkish context and regional issues. With an E-ISSN of 2149-2530 and transitioning to open access in 2022, the journal enhances visibility and accessibility, inviting a global audience of researchers, clinicians, and students to engage with the latest scientific work. The Turkish Thoracic Journal has been indexed in major databases, although it faced a coverage discontinuation in Scopus between 2016 and 2022. Currently positioned within the 23rd percentile among its peers in the field, it invites submissions that explore innovative approaches to thoracic health, enriching the discourse in a vital area of medicine.

Lung Cancer Management

Leading the Charge in Lung Cancer Research and Management
Publisher: FUTURE MEDICINE LTDISSN: 1758-1966Frequency: 4 issues/year

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Lung Cancer-Targets and Therapy

Exploring Innovative Therapies for Lung Cancer
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Lung Cancer - Targets and Therapy, published by Dove Medical Press Ltd, serves as a pivotal Open Access journal dedicated to advancing knowledge and research in the field of oncology, specifically focusing on lung cancer. Since its inception in 2010, this journal has provided a platform for disseminating high-quality research articles, reviews, and clinical studies, thereby enhancing the understanding of lung cancer mechanisms, therapies, and clinical outcomes. Currently ranked in the Q2 quartile within the oncology category and positioned at rank #80 out of 404 in Scopus, it resides in the 80th percentile of its field, reflecting its significant impact and relevance. With a commitment to promoting innovative therapies and strategies, Lung Cancer - Targets and Therapy is an essential resource for researchers, healthcare professionals, and students eager to contribute to the evolving landscape of cancer treatment and research.

World Journal of Clinical Oncology

Advancing the Future of Oncology Research
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Journal of the National Cancer Center

Connecting Researchers to Combat Cancer Effectively.
Publisher: ELSEVIERISSN: 2667-0054Frequency: 4 issues/year

Journal of the National Cancer Center, published by Elsevier, serves as a pivotal platform in the fields of Cancer Research, Hematology, and Oncology. With an ISSN of 2667-0054, this esteemed journal is recognized for its exceptional quality, achieving a Q1 ranking in all categories as of 2023. Its impressive Scopus rankings place it among the top journals in its field, notably holding rank #11 in Medicine - Hematology and rank #36 in Medicine - Oncology. Addressed from Amsterdam, Netherlands, the journal aims to disseminate cutting-edge research and innovative findings that advance the understanding and treatment of cancer, bridging gaps between laboratory discoveries and clinical applications. Although it follows a subscription model, the journal's commitment to accessibility ensures that valuable knowledge reaches healthcare professionals and researchers globally. By fostering collaboration and facilitating knowledge exchange, the Journal of the National Cancer Center is indispensable for those dedicated to combating cancer and enhancing patient care.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Elevating knowledge in cellular and molecular lung physiology.
Publisher: AMER PHYSIOLOGICAL SOCISSN: 1040-0605Frequency: 12 issues/year

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, published by the American Physiological Society, stands as a prominent peer-reviewed journal dedicated to advancing the field of lung cellular and molecular physiology. With an impressive impact factor, the journal serves as a crucial platform for disseminating high-quality research focused on the intricate mechanisms underlying pulmonary function and disease. Established in 1989, this journal has consistently ranked within the top quartiles across various categories, including Q1 in Physiology and Pulmonary and Respiratory Medicine, highlighting its significance in the scientific community. The journal covers a wide scope of topics pertinent to cell biology and physiology, catering to the needs of researchers, professionals, and students seeking to explore and contribute to this vital area of study. Although currently not offering open access, it provides comprehensive access options for subscribers, ensuring that vital research is communicated effectively to the global scientific community. With a commitment to fostering innovation and inspiring future studies, the AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY remains an essential resource for those engaged in lung research.